key: cord-0990933-ui7in5p7
authors: Turecek, Peter L.; Hibbett, Deborah; Kreil, Thomas R.
title: Plasma procurement and plasma product safety in light of the COVID‐19 pandemic from the perspective of the plasma industry
date: 2022-03-17
journal: Vox Sang
DOI: 10.1111/vox.13267
sha: 6d1fb80d034dbaa43b9da1f3dedc2e91fa9122aa
doc_id: 990933
cord_uid: ui7in5p7

This review, written from the perspective of the plasma industry, discusses plasma procurement and plasma product safety in light of the COVID‐19 pandemic. The COVID‐19 pandemic impacted the whole world and, therefore, not unexpectedly, the pharmaceutical industry too. In spite of this, the plasma protein industry has continued to provide life saving therapies to critically ill patients. Moreover, companies have collected COVID convalescent plasma (CP) to support development of investigational therapies, for example, hyperimmune globulins to potentially treat SARS‐CoV‐2 infection, and collaborated with those collecting COVID CP for direct transfusion, which has been made available under emergency use in the United States. For plasma that is fractionated to become a therapy, general knowledge of coronaviruses and numerous new studies on the structure and function of SARS‐CoV‐2 provide reassurance that existing industry precautions, including donor selection, as well as virus inactivation and removal steps during the manufacturing process are sufficient to maintain the high standards of virus safety of plasma products. The pandemic also revealed the vulnerability and inadequacy of the current plasma ecosystem. There is a need for more plasma to be collected around the world to meet the growing need for safe and efficacious plasma‐derived therapies. This requires outdated regulatory and policy restrictions to be realigned with current scientific evidence. More countries around the world should be in a position to contribute to global supply of plasma so that patients with life‐threatening conditions ‐ and often no alternative therapeutic solutions ‐ have better access to care.

The production of plasma products depends on a diligently planned, complex system of willing donors, donation facilities, global manufacturing networks and pharmaceutical product distribution channels, which is largely robust under normal circumstances. However, since the advent of the coronavirus disease pandemic in late 2019 , the situation has been challenged. From early 2020, the pandemic significantly impacted the balanced and welldeveloped system of plasma procurement in ways not previously experienced, further hindering the industry's ability to keep pace with growing patient demand for these life-changing therapies. Challenges included the disruption of donor networks and blood/plasma donation, as well as supply chain networks, leading to reduced supply of plasma and plasma therapies. Local and global travel and trade restrictions hampered the acquisition of source plasma and reduced the available number of blood donations from which recovered plasma is obtained. In turn, this impacted pharmaceutical manufacturing and distribution by interfering with global supply channels of raw materials and devices, and affected the delivery of final drug products to the patients [1] [2] [3] . In parallel, global demand for plasma products has continued to grow across approved indications as a result of broader access in more countries and more patients with rare diseases being diagnosed. The notion that convalescent plasma (CP) and hyperimmune globulin products could be viable treatment options for COVID-19 patients has further increased the demand for plasma [4] [5] [6] . Moreover, with only a small percentage of the 3000+ proteins [7] circulating in plasma being used therapeutically today, research is currently under way to unlock the untapped potential in plasma to support treatment for many diseases such as rheumatoid arthritis, sickle cell anaemia and age-related macular degeneration [8] [9] [10] . Cumulatively, this is creating additional strain on sourcing this scarce lifechanging resource.

In the early 1980s, recipients of biopharmaceuticals derived from human plasma were devastated by widespread infections with the human immunodeficiency virus (HIV) and hepatitis C virus (HCV), which were transmitted through plasma-derived concentrates sourced from virus-carrying donors. Recognition of this serious problem led to major changes in procedures for donor screening and testing and the validation of new process steps embedded into the manufacturing processes of plasma derivatives to remove or inactivate blood contaminants such as viruses and even prion agents [11] . The occurrence of new infectious and transmissible agents always alerts recipients, regulators, prescribers and manufacturers of blood products. This is what happened with SARS-CoV-2: The potential for transmission by transfusion and, therefore, blood derivatives prompted serious considerations towards the safety of blood and plasma products.

In this review, we assess the impact of the COVID-19 pandemic, and particularly the causing pathogenic SARS-CoV-2 on procurement of plasma for fractionation from the plasma industry perspective and focus specifically on sustaining supply of safe and efficacious plasmaderived medicines. Information was collected by literature search in PubMed ® (https://pubmed.ncbi.nlm.nih.gov/; cut-off date, 10 January 2022), web search and personal communication of the authors who are connected to the specialist network of the plasma industries.

The severe acute respiratory syndrome (SARS) called COVID-19 is induced by SARS-CoV-2, which belongs to the group of β-coronaviruses. The virus has a single-stranded genome of about 26-32 kb (+ssRNA), which is the largest known genome size of an RNA virus. Coronaviruses belong to the order Nidovirales, family Coronaviridae and the subfamily Coronavirinae, which consists of α-, β-, γand δ-coronaviruses [12] . Coronavirus was first isolated from chicken in 1937. Before the SARS outbreak in February 2003, coronavirus was not considered highly pathogenic to humans [13] . Since 2002, three zoonotic outbreaks have been caused by β-coronaviruses:

SARS-CoV in 2003 [14] , MERS-CoV in 2012 [15] and the latest outbreak of SARS-CoV-2 at the end of 2019 [16] . There is ongoing debate about the origin of SARS-CoV-2 and a final assessment has not been made, but it seems likely that SARS-CoV-2 is a new evolutionary branch of coronaviruses originating from bats [17] . Despite their genomic differences, coronaviruses share a common structure.

Human coronaviruses contain phosphorylated nucleocapsid (N) protein with genomic RNA as core enveloped by phospholipid bilayers to form spherical or pleomorphic particles of 80-120 nm size and outer surface-projected spike (S) proteins [18] .

ways. There is no reported evidence for the transmission of respiratory viruses, including the influenza viruses and the coronaviruses responsible for SARS (SARS-CoV) and Middle East respiratory syndrome (MERS) (MERS-CoV), by blood and blood components including plasma and plasma-derived medicinal products (PDMPs) [19] [20] [21] .

Testing of blood donations for the absence of infectious agents plays a vital role in providing safe blood for transfusion. Blood services are constantly on alert for the reported detection of emerging pathogens that may impact the safety of the blood supply [22] . When there is a risk that an infectious agent may be transmitted by blood transfusion, this may trigger the implementation of additional screening of donors and testing of blood donations. The best example in this regard was To mitigate the impact of these emerging pathogens on the safety of the blood supply in a timely and effective manner, an effective interaction between all stakeholders, that is, blood services, regulatory authorities, public health institutions and industry, has been

established. An example of this was the epidemic occurrence of the WNV, which first appeared in the United States in 1999 and has since spread across the entire country, resulting in thousands of cases of disease. By 2002, it was clear that the virus could be transmitted by blood transfusion, and by the middle of 2003, essentially all blood donations were being tested for WNV [23] . Subsequently, the resulting plasma products like immune globulins were tested for neutralizing antibody titers in plasma-derived intravenous immune globulin released in the United States during 2003-2008. Antibody titers correlated closely with the cumulative incidence of past WNV infection in blood-and plasma donors, with the lots released in 2008 indicating a seroprevalence of 1% [24] . Similarly, upon the occurrence of the corona pandemic, the discussion around testing of blood and blood derivatives for SARS-CoV-2 started early in 2020 [25] .

While there was much uncertainty at the beginning of the pandemic, as it had been unclear whether SARS-CoV-2 could be transmitted from those with pre-symptomatic or asymptomatic infection, some tangible data have become available as of now. In May 2020, researchers from China found no evidence of SARS-CoV-2 RNA in the blood of donors in a multi-centre study in the province of Hubei 

RT-PCR tests from nose or throat swabs resembling the viral load in the upper respiratory tract [28] . However, detection of vRNA has also been reported in blood, serum and plasma [29, 30] Donor acceptance and deferral criteria and blood screening procedures need to be balanced to provide optimal safety for both donors and recipients while at the same time ensuring an adequate supply of blood products [32, 33] .

Early in the corona pandemic, Chinese authors discussed evidence and understanding of the transmission of SARS-CoV-2 through blood products, and also pathogen inactivation methods on coronaviruses. Although coronaviruses usually infect the upper or lower respiratory tract, the presence of vRNA in plasma or serum is possible, although infectivity has never been detected. Therefore, the risk of transmission of coronaviruses through the transfusion of blood products is theoretical. Given that many asymptomatic infections are found among COVID-19 cases, donor selection would fail under the current circumstances. So far, donation testing for plasma has not been implemented. Testing has not even been required for blood donations, that is, directly transfused components without any virus reduction before application to recipients. Low amounts of vRNA were only rarely found in blood donations (1:100,000) and did not result in transfusion transmission. No infectivity was observed in inoculated permissive cell cultures, indicating no risk of transmission of the infection by blood components including plasma [26] .

In low-and middle-income countries, an increase of blood donations from voluntary, unpaid donors to cover the unmet demand for red blood cell concentrates was observed because of global efforts [34, 35] . However, there is a continuous but slow decline in demand for red blood cells in high-income countries, and with the economic developments across the world, the decline in blood collection will likely continue [36] . Consequently, the amount of available recovered plasma used for plasma fractionation appears to decline. Simultaneously with the rise of the first wave of infections of the corona pandemic, a substantial decrease in the blood supply was observed. For example, in the Hubei province in China, the number of donations was 86% lower in February 2020, dropping from 34,059 to 4778. In some cities in the province, the reduction could reach 90% or even 95% [26] . Until April 2020, the number of donations gradually recovered but did not reach the numbers of the corresponding period of the earlier years. Similar observations were reported from all parts of the world but with varied numbers [37] [38] [39] . This caused a dramatic call to action by the International Foundation of Patient Blood Management (IFPBM) and the Society for the Advancement of Blood Management (SABM) Work Group, urging regional and national shortage plans worldwide and, more vitally, dissemination of knowledge and immediate implementation of patient blood management to optimize medical and surgical patient outcomes by clinically managing and preserving a patient's own blood [40] . Along that line, the UK National Blood Transfusion Committee provided a framework and triage tool to guide the allocation of blood for patients with massive haemorrhage during severe blood shortage. The goal of this document was to provide blood transfusions in an ethical, fair and transparent manner to ensure that the greatest number of life-years were saved [41] .

Reduced or constant availability of recovered plasma before the corona pandemic was compensated by a steady increase of source plasma collections, which had improved by a factor of 3.4 from 2000 to 2017 [42] . Plasma supply and demand are held in fine balance. If demand exceeds supply, or in cases of disruptions in the supply chain, shortages of plasma-derived products can occur [43] . In the past, shortages of plasma-derived coagulation factors and albumin concentrates have altered medical practice. In recent years, intravenous immunoglobulin has been in short supply [44, 45] [47] . Some preliminary observations of treatment with CP therapy resulted in a clinically relevant increased risk of severe adverse events, prompting uncertainty whether CP would be beneficial for people admitted to hospital with COVID-19 [48] . In contrast, other studies have shown that CP could provide a safe and efficacious therapy, improving outcomes in severe SARS-CoV2 infection (e.g., [49] ). A recent systematic review and meta-analysis of randomized clinical trials investigated the association between CP treatment and mortality and concluded that CP treatment of patients with COVID-19 did not reduce all-cause mortality [50] . Commonly, all studies have shown that most CP donations had high neutralizing antibody titers. Pre-testing of donations by ELISA which correlated to the neutralization titre with a certain threshold could be used to eliminate lower titre units, thus enabling an adequate pooling strategy of CP to level out variations of antibody titres and quality in the therapeutic units [51] .

As plasma concentrates are the preferable alternative to whole plasma for safety, efficacy and convenience reasons, hyperimmune globulins Regrettably, the trial did not meet its endpoint to show meaningful improvement in the clinical status of hospitalized adult COVID-19 patients through treatment with an H-Ig when given with standard of care including remdesivir [52] . Importantly, this outcome should not be interpreted as negating the value of plasma in approved indications. The particular study design did not prove a clinical benefit of an H-Ig for this targeted COVID-19 patient population in a hospitalized setting. However, it has significantly contributed to scientific understanding and mirrors mixed experience with CP [53] . The antibody treatment approach has thus far demonstrated efficacy at an earlier stage, namely pre-hospitalization, of the disease through trials with monoclonal antibodies. This was not something that was so apparent when the clinical trial was designed and warrants more research for better understanding [54] [55] [56] [57] . 

The COVID-19 pandemic has further exposed the gap between plasma supply and demand, as well as the fragility of a system that is This is known as the Safety Tripod ( Figure 1 ). The Safety Tripod effectively addressed safety concerns of plasma products, and today plasma products feature significant virus safety margins. The concept has proven so successful that it is now equally applied to and codified for cell-based biotechnology manufacturing platforms and increasingly so for advanced therapy medicinal products, such as cell and gene therapies [63] . What does the Safety Tripod mean for SARS-CoV-2?

Selection of lower-risk donors would be virtually impossible but also not necessary, as we have learned that blood donations and therefore also plasma would not transmit SARS-CoV-2. Consequently, also testing would not be required and would also not be helpful, as even the presence of SARS-CoV-2 vRNA would not result in infectious blood.

Nevertheless, blood and plasma donor deferral criteria for individuals having recovered from COVID-19 have been applied as described above.

Coronaviruses states, which also raised concerns around the potential for ZIKV transmission via blood products. Before systematic virus inactivation and removal studies during the manufacture of PDMPs had been performed, risk assessments were made building on similarities between viruses, the so-called model virus concept. In the case of SARS-CoV-2, we do know its structure and function. As explained, the relatively large size and lipid envelope make SARS-CoV-2 highly susceptible to steps with virus inactivation and removal capacity used during the manufacturing processes, such as S/D [64] , low-pH incubation, caprylate, pasteurization [65] or dry-heat treatments [66] , nanofiltration or fractionation processes and others [67] . The effectiveness of these processes has been demonstrated on other lipid-enveloped model viruses that are quite similar to SARS-CoV-2, for example, human coronavirus 229E and OC43, SARS-CoV, and porcine coronavirus TGEV [68, 69] . In a recent publication, an array of effective coronavirus reduction steps during the manufacture of PDMPs was evaluated and discussed [70] . The authors concluded that, together with earlier reports that SARS-CoV and TGEV are effectively inactivated by pasteurization and standard S/D treatment conditions, these studies provide further evidence that various low-pH incubation and nonstandard S/D treatment steps are also effective at inactivating coronaviruses, which, taken together with other safety measures, provide assurance of a high margin of virus safety against SARS-CoV-2 for F I G U R E 1 The so-called Safety Tripod best describes the safety of plasma-derived products relying on three complementary barriers: (1) selection of donors and plasma sources; (2) testing of individual plasma donations, and mini-pools and manufacturing pools using immunological and nucleic acid amplification technologies (NAT) and (3) manufacturing processes that include dedicated virus inactivation and removal steps PDMPs. Thus, the Plasma Protein Therapeutics Association (PPTA) issued a statement in February 2020 -updated in April 2020 -that the SARS-CoV-2 outbreak is not a concern for the safety of plasma protein therapies manufactured by PPTA member companies [21] .

Building on the historical use of plasma in earlier pandemics, the corona pandemic has substantially increased public awareness of the therapeutic use of plasma, although broader understanding of its use remains low. Use of CP and the potential for H-Igs made from CP to treat those at risk of serious complications from COVID-19 have been widely recognized, and this has drawn attention to the importance of blood and plasma as the source of life-saving human therapies.

Data obtained by in-depth investigations of the SARS-CoV-2 virus and derived from studies with highly similar viruses such as the human coronavirus 229E and OC43, SARS-CoV and porcine coronavirus TGEV confirmed that SARS-CoV-2 is not an issue for the safety of plasma derivatives. Several studies have suggested that infectivity will not be found in plasma donated by those individuals undergoing routine selection based on their health status.

There is a need for more plasma to be collected around the world to meet the growing need for safe and efficacious plasma-derived therapies-and this was evident even before the pandemic [71] . As an example, demand for immunoglobulin products is anticipated to grow steadily over the next few years, with an expected increase of 33% from 2017 to 2025. A key factor behind this growth is the growth in the use of immunoglobulins to treat secondary immunodeficiencies, or even cancer [72] . An increase in collections requires outdated regulatory and policy restrictions to be realigned with current scientific evidence. Specifically, several measures originally implemented with the intention to enhance the virus safety margins of PDMPs have now become redundant. This is largely a result of significantly enhanced and fully validated virus inactivation and removal processes that have been embedded into manufacturing processes, as well as advancements in the science of testing for infectious agents. The continued implementation of these measures limits collection of plasma for fractionation. By addressing this, as well as over-reliance on the few countries with regulatory frameworks conducive to effective plasma collection and shifting towards broader country contribution to global plasma supply, we can create a more sustainable plasma landscape. This means more patients around the world with lifethreatening conditions-and often no therapeutic alternative solution-would be able to count on more reliable supply and, therefore, be more confident of access and continuity of care.

Changes in purchases for intensive care medicines during the COVID-19 pandemic: a global time series study

Managing medication supply chains: lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future

The impact of COVID-19 outbreak on the Transfusion Medicine Unit of a Northern Italy Hospital and Cancer Centre

Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic

Factors driving availability of COVID-19 convalescent plasma: insights from a demand, production, and supply model

Antibodies to watch in 2021

The human plasma proteome draft of 2017: building on the human plasma PeptideAtlas from mass spectrometry and complementary assays

Alpha-1 antitrypsin therapy for autoimmune disorders. Chronic Obstr Pulm Dis

Cytokines and plasma factors in sickle cell disease

Regenerative therapy by suprachoroidal cell autograft in dry age-related macular degeneration: preliminary in vivo report

Building blocks of the viral safety margins of industrial plasma products

Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus

Koch's postulates fulfilled for SARS virus

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview

From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses

Risk of Transfusion Transmission of SARS-CoV-2 Is Only Theoretical

Updated Information for Blood Establishments Regarding the COVID-19 Pandemic and Blood Donation. Bethesda

Plasma Protein Therapeutics Association (PPTA). New Coronavirus (SARS-CoV-2) and the Safety Margins of Plasma Protein Therapies

Donation testing and transfusion transmissible infections

West Nile virus among blood donors in the United States

West Nile virus infection in plasma of blood and plasma donors, United States

COVID-19 and blood safety: help with a dilemma

No evidence of SARS-CoV-2 RNA among blood donors: a multicenter study in Hubei

Minipool testing for SARS-CoV-2 RNA in United States blood donors

Laboratory diagnosis of COVID-19: current issues and challenges

Detection of SARS-CoV-2 in different types of clinical specimens

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus

Community blood supply model: development of a new model to assess the safety, sufficiency, and cost of the blood supply

How much blood is needed? Vox Sang

World Health Organization. Home/Newsroom/Fact sheets/Detail/Blood safety and availability

Slowing decline in blood collection and transfusion in the United States -2017

Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State

Blood supply and transfusion support in southern Italy: findings during the first four weeks of the SARS-CoV-2 pandemic

Dwindling blood reserves: an ominous downside of COVID-19 pandemic

Essential role of patient blood management in a pandemic: a call for action

Triage tool for the rationing of blood for massively bleeding patients during a severe national blood shortage: guidance from the National Blood Transfusion Committee

An analysis of the impact of international transfers of plasma on the availability of immunoglobulin therapies. Fall

Supply and demand for plasma-derived medicinal products -a critical reassessment amid the COVID-19 pandemic

Shortage of human intravenous immunoglobulin--reasons and possible solutions

Google Trends as an early indicator for shortages of intravenous immunoglobulin (IVIG)

The United Kingdom Primary Immunodeficiency Network (UKPIN) Official Release

Treatment for emerging viruses: convalescent plasma and COVID-19

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Early transfusion of convalescent plasma improves the clinical outcome in severe SARS-CoV2 infection

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

Experience with COVID-19 convalescent plasma provides vital guidance to future pandemics. Transfusion

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19

Plasma Protein Therapeutics Association (PPTA). Advocacy Toolkit

key-economic-and-valueconsiderations-for-plasma-derived-medicinal-products-PDMPs-in-Europe_Vintura-and-PPTA.pdf 60. Guidance for Industry: Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products

Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates

NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Risk factors for retrovirus and hepatitis virus infections in accepted blood donors

Viral contamination in biologic manufacture and implications for emerging therapies

SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation

Effective inactivation of a wide range of viruses by pasteurization

Heat sensitivity of a SARS-associated coronavirus introduced into plasma products

Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment

Effect of pH and temperature on the infectivity of human coronavirus 229E

Studies with human coronaviruses. II. Some properties of strains 229E and OC43

Effective coronavirus reduction by various production steps during the manufacture of plasma-derived medicinal products

The Economist

Available from: https://marketingresearchbureau. com/forecast-of-the-global-immunoglobulin-igg-market-2023-2/ How to cite this article: Turecek PL, Hibbett D, Kreil TR. Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry

All authors conceived, wrote and edited the manuscript. We thank Wolfhard Erdlenbruch for critically reviewing the manuscript. We are also grateful to Roger Brinser, Bernhard Kohli, Ali Mardini, Robert